Literature DB >> 22042700

Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.

Alvin C Ng1, Sundeep Khosla, Natthinee Charatcharoenwitthaya, Shaji K Kumar, Sara J Achenbach, Margaret F Holets, Louise K McCready, L Joseph Melton, Robert A Kyle, S Vincent Rajkumar, Matthew T Drake.   

Abstract

Recent population-based studies demonstrate an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS). The etiology of this increased risk remains unclear, however, because areal bone mineral density (aBMD) measurements by dual-energy x-ray absorptiometry cannot assess bone microstructural properties critical to determining bone quality and strength. To better define the skeletal effects of MGUS, we performed aBMD and high-resolution peripheral quantitative computed tomography volumetric bone mineral density (vBMD) measurements in 50 MGUS patients (20 females, 30 males; mean ± SEM age, 70.5 ± 1.4 years) and 100 matched control subjects. Relative to controls, MGUS patients had decreased aBMD at the femoral neck (P = .05) and total femur (P < .05) but no differences at other sites. In contrast, high-resolution peripheral quantitative computed tomography showed markedly diminished cortical thickness (P < .05) and increased endocortical area (P < .01). Average vBMD (P < .01), cortical vBMD (P < .001), and trabecular thickness (P < .01) were all significantly decreased in MGUS patients, suggestive of impaired bone formation. Serum levels of the Wnt pathway inhibitor Dickkopf-related protein 1 (P < .001) and osteoclast-activating factor MIP-1α (P < .05) also were significantly elevated in MGUS patients. Our data provide the first evidence of altered bone microstructure in MGUS and suggest that cytokines elevated in osteolytic myeloma also may be associated with bone loss in MGUS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042700      PMCID: PMC3242716          DOI: 10.1182/blood-2011-04-351437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

Authors:  D O'Shea; C Giles; E Terpos; J Perz; M Politou; V Sana; K Naresh; I Lampert; D Samson; S Narat; E Kanfer; E Olavarria; J F Apperley; A Rahemtulla
Journal:  Bone Marrow Transplant       Date:  2006-04       Impact factor: 5.483

Review 2.  Bone strength: current concepts.

Authors:  Charles H Turner
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

3.  Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.

Authors:  Marianna C Politou; Deborah J Heath; Amin Rahemtulla; Richard Szydlo; Athanasios Anagnostopoulos; Meletios A Dimopoulos; Peter I Croucher; Evangelos Terpos
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

4.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

5.  Fracture risk in patients with monoclonal gammopathy of undetermined significance.

Authors:  Henrik Gregersen; Paw Jensen; Mette Gislum; Birgit Jørgensen; Henrik Toft Sørensen; Mette Nørgaard
Journal:  Br J Haematol       Date:  2006-08-22       Impact factor: 6.998

6.  Ridge number density: a new parameter for in vivo bone structure analysis.

Authors:  A Laib; T Hildebrand; H J Häuselmann; P Rüegsegger
Journal:  Bone       Date:  1997-12       Impact factor: 4.398

7.  Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance.

Authors:  Jessica Pepe; Maria Teresa Petrucci; Italo Nofroni; Valeria Fassino; Daniele Diacinti; Elisabetta Romagnoli; Salvatore Minisola
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

8.  Fracture risk with multiple myeloma: a population-based study.

Authors:  L Joseph Melton; Robert A Kyle; Sara J Achenbach; Ann L Oberg; S Vincent Rajkumar
Journal:  J Bone Miner Res       Date:  2004-11-29       Impact factor: 6.741

Review 9.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

Authors:  Angela Rogers; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2005-08-16       Impact factor: 5.958

10.  Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography.

Authors:  A Laib; P Rüegsegger
Journal:  Bone       Date:  1999-01       Impact factor: 4.398

View more
  37 in total

Review 1.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 2.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

3.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

Review 4.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

5.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

Review 6.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 7.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

Review 8.  What is the significance of monoclonal gammopathy of undetermined significance?

Authors:  Catherine Atkin; Alex Richter; Elizabeth Sapey
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

9.  The ecology of cancer from an evolutionary game theory perspective.

Authors:  Jorge M Pacheco; Francisco C Santos; David Dingli
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

Review 10.  Clinical utility of serum sclerostin measurements.

Authors:  Bart L Clarke; Matthew T Drake
Journal:  Bonekey Rep       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.